Public Relations (PR)
Three suggestions for defusing the highly charged pricing atmosphere
Theranos posted the lengthy response on the news section of its website on Thursday, then bragged on Twitter that its statement was 3,000 words longer than the WSJ story.
The drugmaker, which recently drew scrutiny from lawmakers, is planning to change some of its most contentious business practices. Experts say Valeant also needs to educate lawmakers and the public about the value of its medicines.
Sherry Goldberg will replace her as New York market leader.
Kristie Kuhl, previously EVP at Cohn & Wolfe, is tasked with building out the agency's pharmaceutical business.
Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise
Craig Rothenberg joined Turing as its first comms chief less than two months ago.
Stakeholder activists, social media and an increasingly global market are three defining issues for companies operating in the 21st century.
Holland most recently worked as executive director of public health solutions at WebMD.
After two decades at Johnson & Johnson, Craig Rothenberg talks about joining a startup and the role of comms in pharma.
Walgreens Boots Alliance's global comms team works hand in hand to balance the complexities of a merger and create a unified strategy to inspire all stakeholders.
Contrary to popular belief, Addyi is not the female Viagra. That's the message drug-maker Sprout must get across to doctors and patients in the coming weeks.
ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.
From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.
It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.
Weber Shandwick hired Susan Smirnoff away from the healthcare practice of Ruder Finn, where she had spent more than three decades.
The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.
Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.
The drug maker says it has spoken to Deen about her racist comments, but an opaque company statement indicates the Danish firm has not cut ties with the now-former Food Network star.
Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.
GSK says 2013 will be a springboard for future growth, Burson-Marsteller hands out two new executive titles.
OraSure, the maker of the recently-approved home HIV test, has hired an experienced consumer marketer from Pfizer to head up the launch as it readies a TV ad campaign.
Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.
The FDA has issued a rare untitled letter concerning a pitch letter - a reminder that the agency does not consider press materials to be exempted from its oversight.
The fan base of the AMA's publishing arm grew 115% in the second quarter.
The non-profit announced Thursday that it is on the hunt for a new president and two new board members, and that its beleaguered CEO will step down.
Roche shutters its Nutley, NJ, R&D site, and Porter Novelli names a new CEO.
An analysis of the FDA's handling of the Vytorin debacle points to a need for better public-health warnings about medications, researchers say.
A global study of consumer attitudes towards health found evidence for the "empowered consumer" hypothesis, with respondents expressing a greater sense of control over and responsibility for their health.
The most recent Johnson & Johnson recall may officially be CEO William Weldon's last. Alex Gorsky will become CEO as of April 26, the company said, and Weldon will stay on as chairman of the board of directors.
Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.